Navicixizumab
- CAS No.
- 1638338-43-8
- Chemical Name:
- Navicixizumab
- Synonyms
- Navicixizumab;Navicixizumab (anti-DLL4);Research Grade Navicixizumab;Research Grade Navicixizumab (DHJ65303)
- CBNumber:
- CB88080974
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| FDA UNII | 1W14T9L25W |
|---|
Navicixizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0623918 | Navicixizumab 99.83% | 1638338-43-8 | 1mg | $542 | 2026-06-04 | Buy |
| ChemScene | CS-0623918 | Navicixizumab 99.83% | 1638338-43-8 | 5mg | $1733 | 2026-06-04 | Buy |
| ChemScene | CS-0623918 | Navicixizumab 99.83% | 1638338-43-8 | 10mg | $2773 | 2026-06-04 | Buy |
| aablocks | AA02EO83 | NAVICIXIZUMAB ≥95%(SDS-PAGE&SEC-HPLC) | 1638338-43-8 | 1mg | $664 | 2026-06-03 | Buy |
| aablocks | AA02EO83 | NAVICIXIZUMAB ≥95%(SDS-PAGE&SEC-HPLC) | 1638338-43-8 | 5mg | $2380 | 2026-06-03 | Buy |
Navicixizumab Chemical Properties,Uses,Production
Uses
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].
in vivo
Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth[3].
References
[1] Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. DOI:10.1200/JCO.21.01801
[2] Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. DOI:10.21037/atm-20-4497
[3] Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.
Navicixizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Navicixizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 6206333 13167063860 | anhua.mao@aladdin-e.com | China | 43293 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5550 | 58 |
| Olix ( Hubei) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9769 | 58 |
